November 20, 2025

New study finds Ozempic and Mounjaro protect the heart too

IntelME Verdict

Clinical Benefit

TL;DR

New study reveals GLP-1-based drugs Ozempic and Mounjaro not only aid weight loss but also reduce heart attack and stroke risk in type 2 diabetes patients, offering significant heart protection benefits.

Analysis

The study showcasing heart protection benefits of Ozempic and Mounjaro beyond weight loss is a significant clinical benefit for biotech/pharma. This finding could lead to expanded indications, increased market potential, and improved patient outcomes, positioning these GLP-1-based drugs as valuable assets in managing cardiovascular risks in type 2 diabetes.

Source

ScienceDaily↗